At 71 years old, facing a terminal diagnosis, Colorado resident Tom Pringle has one more thing he wants to do before he dies: ...

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...

According to Brain Chemistry Labs, the in-the-works test can identify an ALS patient with 97% accuracy. The next step is to ...

VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S.

Two people who filed formal complaints about the Dr. Goodenowe Restorative Health Center in Moose Jaw, Sask. are asking why ...

Qalsody shows long-term benefits for some SOD1-ALS patients. Early Qalsody treatment improved physical function, lung function, and muscle strength. Early initiation also delayed major disease ...

Introduction The functional cure of chronic hepatitis B (CHB) is an ideal goal of therapy, as it is associated with improved long-term outcomes. Patients with low levels of HBsAg have higher rates of ...

The Fresh Toast - the latest on medical cannabis and ALS explores symptoms, research, patient relief options, and emerging ...

"I didn't know all the details like I do now, but I knew enough about ALS to know that there wasn't a cure," Gayheart shared. Mekishana Pierre is a news writer at Entertainment Weekly. She has been ...

QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to ...